Compare GLDD & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | ALVO |
|---|---|---|
| Founded | 1890 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2007 | N/A |
| Metric | GLDD | ALVO |
|---|---|---|
| Price | $17.01 | $3.33 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.00 | $8.00 |
| AVG Volume (30 Days) | ★ 2.5M | 357.3K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $5.19 | $13.28 |
| Revenue Next Year | $7.56 | $18.63 |
| P/E Ratio | ★ $15.74 | $18.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.37 | $3.03 |
| 52 Week High | $17.02 | $11.85 |
| Indicator | GLDD | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 45.45 |
| Support Level | $14.60 | $3.10 |
| Resistance Level | N/A | $3.93 |
| Average True Range (ATR) | 0.03 | 0.20 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 80.00 | 30.97 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.